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Abstract: Erdheim–Chester disease (ECD) is a rare histiocytic disorder, characterized by 
the xanthomatous infiltration of tissues by CD68-positive and CD1a-/CD100-negative foamy 
histiocytes. In childhood, ECD is exceptionally rare, and only a dozen cases have been published 
so far. The cooccurence of Langerhans cell histiocytosis (LCH) and ECD is even rarer. Here, 
we report a 2-year-old boy, the youngest patient in the literature so far, who was diagnosed with 
concomitant BRAF mutation-positive LCH and ECD. In his case, conventional LCH treatment 
proved to be ineffective, but he is the youngest patient who was successfully treated with the 
BRAF inhibitor vemurafenib.
Keywords: vemurafenib, treatment, Erdheim–Chester disease, Langerhans cell histiocytosis, 
pediatric histiocytic disorders
Abbreviations
ECD, Erdheim–Chester disease; IFN-alpha, interferon-alpha; LCH, Langerhans cell 
histiocytosis; MRI, magnetic resonance imaging; OIS, oncogene-induced senescence.
Introduction
ECD is a rare non-Langerhans histiocytic disorder, which typically causes bone lesions, 
but virtually any organ can be involved, and the presentation symptoms may be also 
varied, ranging from asymptomatic to multisystem, life-threatening forms. Although, 
according to the WHO classification, ECD is a neoplasm deriving from CD68-positive 
and CD1a- and S100-negative histiocytes, the exact pathogenesis has not been fully 
clarified yet, whether it has a malignant nature or an inflammatory nature.1 In recent 
years, a growing number of studies that have investigated the underlying mechanisms 
of ECD have identified an activating point mutation of BRAF V600E in .50% of 
ECD patients. This has given a basis for encouraging targeted therapies. The BRAF 
inhibitor vemurafenib has demonstrated activity in small cohorts of adults treated with 
multisystem and refractory ECD.2,3 Data about the usage and efficacy of vemurafenib 
in pediatric ECD are lacking. We report an excellent therapy response to vemurafenib 
in a 2-year-old ECD patient, who is the youngest patient in the literature so far.
Case report
A 20-month-old boy was presented with visible soft masses on the left temporal 
and right parietal bone after a ~1-year-long history of “seborrheic dermatitis” of the 
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scalp, “diaper rash”, and recurrent episodes of upper airway 
infections and otitis media. MRI revealed a 5×5×2.5 cm 
size frontal destructive mass on the right, a 6×3×2 cm size 
frontotemporoparietal mass, and a 1×1×1 cm size frontal 
mass on the left side, and all of them caused bone lesions 
(Figure 1A and B). Based on the patient history, physical 
findings, and imaging studies, LCH came up as a possible 
diagnosis with skin and multifocal bone involvement, which 
was confirmed histologically: the biopsy specimen from 
one of the skull masses was histologically composed of 
Figure 1 The role of head MrI in the evaluation of therapy response.
Notes: (A) T2W image shows left temporal bone involvement of LCH (white arrow). (B) This lesion shows inhomogenous diffusion restriction (black arrow) on the 
diffusion-weighted image. (C and D) Normal appearance of the left temporal area after the initial chemotherapy on T2W and diffusion-weighted images. (E and F) signal 
abnormality in the left temporal area on the T2W (white arrow) and diffusion-weighted (black arrow) images.
Abbreviations: LCH, Langerhans cell histiocytosis; MrI, magnetic resonance imaging.
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CD1a- and S100-positive mononuclear cells with coffee 
bean-shaped nuclei, eosinophil granulocytes, and multi-
nucleated giant cells (Figure 2A and B). Morphology and 
immunophenotype were typical for LCH. Furthermore, 
skeletal manifestations and solid organ involvement were 
excluded by bone scintigraphy and MRI. We started his 
chemotherapy based on LCH-III protocol’s appropriate arm, 
according to the risk of the disease. Thanks to the effectivity 
of the therapy, rapid regression of the skull masses was 
detectable in the beginning (Figure 1C and D), but in the 
fourth month of chemotherapy, hepatosplenomegaly, hyp-
albuminemia, serious pancytopenia occurred, the activity 
of the left frontal bone lesion came back (Figure 1E and F), 
and the skin symptoms flared up. Bone marrow biopsy was 
negative at that time. Thereafter, he required dose reduc-
tion of cytostatic drugs, his transfusion need was extreme, 
and he required platelet support almost daily and blood 
transfusion regularly as well. He required albumin products 
for severe hypalbuminemia, desferoxamine treatment for 
secondary hemosiderosis, hospital care almost continuously 
for frequent septic episodes, and durable heparin therapy for 
deep vein thrombosis. Due to the serious symptoms, we were 
forced to stop cytotoxic therapy and started corticosteroid 
maintenance therapy with indomethacin supplementation 
for a short period, which was stopped because of its plate-
let aggregation inhibitory effect and simultaneous gravis 
thrombocytopenia. Eight months after the initial diagnosis, 
splenectomy was performed due to symptoms of hypersple-
nia, and histology confirmed splenic fibrosis represented by 
multiple fibrohistiocytic nodules composed of foamy mac-
rophages loaded with hemosiderin accompanied by maturing 
extramedullary hematopoiesis. Bone marrow biopsy at the 
same time revealed highly similar pathological findings: 
excessive (~75%) engagement of marrow by CD68-positive 
and CD1a- and S100-negative macrophages inducing mild 
fibrosis. These macrophages had water clear wide cytoplasm 
and rounded nuclei (Figure 3A and B). A significant number 
of Langerhans cells were not detected in these bone marrow 
and spleen samples. On plain radiograph of the painful 
knees, symmetric osteosclerosis could be seen (Figure 4A). 
Figure 2 skull lesion in LCH.
Notes: (A) Hematoxylin–eosin stain. Majority of the cells have coffee bean-shaped nuclei with open chromatin pattern and nuclear membrane grooves. (B) strongly positive 
CD1a immune reaction, which is specific for LCH.
Abbreviation: LCH, Langerhans cell histiocytosis.
Figure 3 Massive bone marrow infiltration with ECD (original magnification).
Notes: (A) Hematoxylin–eosin stain. The marrow spaces are extensively engaged by foamy macrophages. (B) s100 immune reaction. The immune phenotype of macrophages 
is consistent with the phenotype of the conventional tissue histiocytes (CD68 positive, S100 negative). S100 is a highly sensitive but a nonspecific marker of Langerhans cells, 
therefore a good marker for screening Langerhans cells, or exclude Langerhans cell origin of a tumorous proliferation.
Abbreviation: eCD, erdheim–Chester disease.





Interestingly, low signal intensities could be seen in all 
visualized bones (not only in the long bones) on every MRI 
sequence (Figure 5). These findings raised the diagnosis of 
non-Langerhans cell ECD with extensive bone marrow and 
spleen involvement. BRAF V600E mutation positivity was 
confirmed by pyrosequencing in the initial LCH skull lesion 
and in the recent ECD bone marrow biopsy specimen as well. 
According to the diagnosis and the literature, we started IFN-
alpha therapy, and then, in default of clinical improvement 
and after obtaining the result of BRAF V600E mutation posi-
tivity of his disease, we stopped IFN-alpha administration and 
started BRAF inhibitor vemurafenib therapy (according to 
the license by National Institute of Pharmacy and Nutrition; 
license number: OGYI/40060-1/2014). As there are no data 
about the pediatric dosage of vemurafenib, we calculated it 
by correlating the child’s body surface with the adults’ 2 m2 
body surface and the associated adult dose (240 mg BID for 
0.73 m2 body surface). Within a few days, we observed a 
rapid and impressive improvement in the general state; after 
4 days of vemurafenib treatment, his thrombocyte count 
started to increase, and he did not require transfusions any 
more. The control bone marrow histological examination 
after 3 months of BRAF inhibitor therapy showed 60% 
residual disease, which decreased to 15% in the 11th month. 
In the 16th month of vemurafenib therapy we could detect 
complete remission in the bone marrow, which was also 
verified by BRAF mutation analysis. Our findings reveal that 
the histological disappearance of the disease from the bone 
marrow can last for several months; however, the radiological 
improvement takes a couple of weeks/month (Figure 4B), 
and the positive clinical response is the first indicator of the 
effective treatment. This improvement could be seen in a 
couple of days after starting the vemurafenib therapy.
Now the patient is 4 years old, and he is in the 18th 
month of vemurafenib therapy given in the same dose 
Figure 5 Coronal T2W image of the spine shows very low signal intensity of the 
bone marrow that is specific for ECD.
Abbreviation: eCD, erdheim–Chester disease.
Figure 4 plain radiograph of the knees (A) before and (B) after vemurafenib treatment.
Notes: (A) Bilateral, symmetric, irregular sclerotic changes in the metaphysis of the bones. (B) Normal bone structure with a radiolucent band and small cystic lesions next 
to the epiphyseal plates.
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from the beginning. His general status is excellent, no 
hepatosplenomegaly is found, blood count and routine labo-
ratory parameters are normal, and his ECD is in complete 
remission. The detected side effects of vemurafenib are the 
lack of eyebrows, very dry, rough skin all over the body, 
and hypertension.
As there is no experience with the long-term use of 
vemurafenib in the literature and it can cause serious side 
effects, regarding the young age and the high-risk disease 
of our patient, the National Pediatric Stem Cell Transplanta-
tion Committee decided to treat him with allogenic stem cell 
transplantation; hence, the search for an appropriate donor is 
in progress. Parents’ consent has been obtained for the publi-
cation of this case report and its accompanying images.
Discussion
ECD is a rare histiocytic disorder, and since its first descrip-
tion in 1930, ~500 cases have been reported in the literature,4 
and there are only a few publications about pediatric ECD 
patients.5–10 The pathogenesis is still incompletely under-
stood, and there are an increasing number of contradictory 
results supporting a theory of either a reactive origin or a 
malignant origin. Recent discovery of the high prevalence of 
BRAF V600E oncogenic mutation in ECD and LCH but not 
in other histiocytic disorders suggests that both proliferations 
could derive from a common origin.11–13 In addition to the 
recognized oncogenic activity of BRAF V600E mutation, 
it has also been associated with OIS, a recently identified 
important mechanism against tumor proliferation. As a cru-
cial part of this antitumor activity, BRAFV600E-mutated 
cells produce a wide range of cytokines and chemokines, 
and this local inflammatory reaction may prevent the 
transformation of the mutated cells to cancer. This hypothesis 
raises the possible rule of OIS in ECD as well.14,15 Although 
ECD can be distinguished from LCH by morphological and 
immunohistochemical evaluation, based on the same clonal 
mutations and similar clinical manifestations, the latest 
updated WHO classification includes them in the same “L” 
(Langerhans) group. Furthermore, studies suggest that the 
occurrence of both diseases in the same patient is not rare, 
and in 12%–20% of patients, they really present as LCH-ECD 
overlap syndrome.12,16,17 Hervier et al17 identified 23 patients 
with mixed histiocytosis, and both diseases (LCH and 
LCD) were diagnosed simultaneously in 11 patients (48%). 
Diagnosis of LCH preceded ECD – similarly to our case – in 
all remaining patients (52%). To our best knowledge, only 
one pediatric double diagnosis has been published so far: in 
2015, Kim et al published a case of a 3-year-old boy with 
intracranial simultaneous LCH and ECD.18 In these mixed 
histiocytosis cases, both LCH and ECD bear the same BRAF 
V600E mutation. These data suggest the theory of the com-
mon clonal origin of these disorders.
As ECD is extremely rare in children, evidence regarding 
treatment is limited to case reports. Successful treatments 
with corticosteroid monotherapy, IFN-alpha, or anakinra 
have been published on a case-to-case basis.5,7–10 Since the 
prognosis of ECD has been reported as poor, search for 
new therapeutic approaches is essential. More than 50% 
prevalence of BRAF mutation in ECD patients gives a 
possible therapeutic target. Clinical experiences with the 
BRAF inhibitor vemurafenib in ECD are rapidly increas-
ing, both in prospective clinical trials and in “off-label” 
administration.12 Initial case reports have demonstrated 
significant activity of vemurafenib in adult ECD patients: 
three different publications reported at least partial response 
following vemurafenib therapy, which involved ~30 ECD 
patients in all with multisystemic, refractory diseases.3,19,20 In 
the case of our patient, corticosteroid and IFN-alpha therapies 
proved to be ineffective, and hence we were forced to change 
to another therapy option. BRAF mutation positivity of his 
ECD gave us a potential therapeutic option, which proved 
to be very effective. Nevertheless, indefinite treatment with 
BRAF inhibition is potentially unsafe, given the risk of 
accelerating premalignant RAS-mediated neoplastic lesions, 
although to date no treatment course has been defined for 
vemurafenib in ECD.12 Attempting vemurafenib treatment 
cession and watch-and-wait attitude were not a real pos-
sibility in his case facing with his very high-risk disease. 
Since 2001, some case reports about autologous stem cell 
transplantation as a therapy in ECD have been published in 
the literature;21,22 in our case, due to extensive bone marrow 
infiltration, allogenic transplantation had to be preferred 
instead of autologous.
Extensive bone marrow involvement in ECD is also not 
common, but the exact frequency is unknown because of 
the rarity of the disease, although case reports have been 
published in 2016 about bone marrow involvement in two 
adult ECD patients.23,24
Recent publication reports the youngest ECD patient in 
the literature, and this is the first one about the successful 
application of the BRAF inhibitor vemurafenib in pediatric 
ECD. The case is also a rarity because of the consecutive 
presence of BRAF-positive LCH and ECD. Furthermore, 
according to our encouraging results with this boy, we 
suggest to think of vemurafenib as a possible, off-label 
therapy in pediatric ECD.
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